B-Technique with dermis suspension: A new approach toward reduction mammaplasty combining short-scar with durability of results.

J Plast Reconstr Aesthet Surg

Department of Obstetrics and Gynecology, Medical University of Vienna, Währinger Gürtel 18-22, 1090 Vienna, Austria.

Published: May 2020

Background: Dermis suspensions (DM) have been introduced in reduction mammaplasties (RM) to extend the durability of the results and improve the quality of the scar. The authors present a new method of RM that consists of completing the B-method of Regnault with a well-vascularized DM.

Objective: Analyze the efficacy of a reduction mammaplasty technique proposed by the authors.

Methods: The authors propose a comparison of two mamma reduction techniques based on a superior pedicle performed on 233 patients at the Medical University of Vienna, Department of Obstetrics and Gynecology, from 2010 to 2019. A total of 102 patients (Group A) were treated with a mammaplasty using Regnault's B-technique with a superior pedicle; 131 patients (Group B) were treated through a similar technique with additional support from an inferior-based deepithelialized pedicle for extra support. The assessment of patient satisfaction was performed by using the BREAST-Q for breast reduction; scar quality assessment was performed using a Patient and Observer Scar Assessment Scale (POSAS).

Results: Group A/Group B: 74/97 patients were operated bilaterally and 28/24 unilaterally. The amount of resected tissue ranged from 102-620 g to 30-810 g. Average BREAST-Q score for satisfaction with outcome was 82.3/86.1. POSAS was scored 35.2/37.6 to 23.2/24.4. Bottoming out after surgery was observed in 12 of 102 patients in Group A and 6 of 131 in Group B in the follow-up visits at 12, 18, and 36 months.

Conclusion: The described technique proved to be fast, safe, and reliable, with a high level of patient satisfaction, less bottoming out, and better scar quality.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bjps.2019.11.045DOI Listing

Publication Analysis

Top Keywords

patients group
12
reduction mammaplasty
8
superior pedicle
8
102 patients
8
group treated
8
patient satisfaction
8
scar quality
8
reduction
5
patients
5
group
5

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China.

Background: The DL-3-n-butylphthalide (NBP), a multi-target neuroprotective drug, improving cognitive impairment in patient with vascular cognitive impairment has been confirmed. The efficacy of NBP in patients with cognitive impairment due to Alzheimer's disease (AD) remains unknown. This study aimed to evaluate the efficacy and safety of NBP in patients with mild cognitive impairment (MCI) due to AD though a clinical randomized controlled trail.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Columbia University, New York, NY, USA.

Background: Focused ultrasound (FUS)-induced blood-brain barrier opening (BBBO) is a technique for safely, non-invasively, and transiently opening the blood brain barrier in a targeted area of the brain. Pre-clinical and clinical studies have shown that FUS is capable of decreasing amyloid plaque load and stimulating neurogenesis in Alzheimer's Disease (AD) models, in addition to being safe for use in human patients. However, the effect of FUS-BBBO on neurons has not yet been characterized, despite its crucial role in cognition and regulating brain function.

View Article and Find Full Text PDF

Background: Dysregulated GABA/somatostatin (SST) signaling has been implicated in psychiatric and neurodegenerative disorders. The inhibition of excitatory neurons by SST+ interneurons, particularly through α5-containing GABAA receptors (α5-GABAAR), plays a crucial role in mitigating cognitive functions. Previous research demonstrated that an α5-positive allosteric modulator (α5-PAM) mitigates working memory deficits and reverses neuronal atrophy in aged mice.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Imperial College London, London, United Kingdom; Division of Neurology, Department of Brain Sciences, Imperial College London, United Kingdom, London, London, United Kingdom.

Background: Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue licensed for the treatment of type 2 diabetes mellitus (T2DM). Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells.

Method: This is a multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild to moderate Alzheimer's dementia, conducted at several centres in the UK.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

NYU Grossman School of Medicine, New York, NY, USA; NYU, New York City, NY, USA.

Background: Astrocytes, a major glial cell in the central nervous system (CNS), can become reactive in response to inflammation or injury, and release toxic factors that kill specific subtypes of neurons. Over the past several decades, many groups report that reactive astrocytes are present in the brains of patients with Alzheimer's disease, as well as several other neurodegenerative diseases. In addition, reactive astrocyte sub-types most associated with these diseases are now reported to be present during CNS cancers of several types.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!